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Abstract: Nitrofurazone (NTZ) is usually employed in the topical treatment of infected wounds and lesions of both skin 
and mucosa. Microencapsulation is a process utilized in the incorporation of active ingredients within polymers aiming at, 
among other objectives, the prolonged release of pharmaceutical compounds and protection from atmospheric agents (viz. 
moisture, light, heat and/or oxidation). With the goal of utilizing the microparticles containing encapsulated NTZ in 
pharmaceutical formulations, one prepared microparticles containing NTZ via ionotropic gelation of sodium alginate. The 
microparticles were characterized via scanning electron microscopy analyses, Fourier transform infrared spectroscopy 
(FTIR) analyses, via determination of encapsulation efficiency, and via thermal analyses (both TGA and DSC). The final 
gel formulation was also characterized rheologically. The extrusion/solidification technique employed to obtain the cal-
cium alginate microparticles with encapsulated NTZ was found to be adequate, and produced an NTZ encapsulation effi-
ciency of ca. 97.8% ± 1.1%. The calcium alginate microparticles thus obtained, with encapsulated NTZ, exhibited an oval 
shape and hydrodynamic diameters between 500 µm and 800 µm. From the thermal analyses performed, together with in-
formation from the infrared spectra, one may conclude that NTZ did not strongly bind to the polymer, which may be fa-
vorable for the release of the active ingredient. From the results obtained in the present research effort, one may conclude 
that the microparticles produced possess the potential to be utilized as carriers for NTZ in pharmaceutical formulations 
such as gels, ointments, and solutions. 
Keywords: Antimicrobial topical applications, calcium alginate, ionotropic gelation, microencapsulation, microparticles, nitro-
furazone. 
1. INTRODUCTION 
 Nitrofurazone (NTZ) for human use is used for the topi-
cal treatment of infected wounds and injuries of the skin and 
mucous membranes. NTZ presents a broad spectrum of ac-
tion, acting against various Gram-positive and Gram-negative 
microorganisms, but its mechanism of action is not fully 
understood. According to Ryan et al. [1], the mechanism of 
action of NTZ may probably be explained by the ability of 
the enzyme azoredutase of several bacterial species to reduce 
nitroaromatic drugs. The disinfectant activity of NTZ pro-
motes healing in the treatment of wounds produced by 
trauma, burn or surgery procedures. This pharmaceutical 
compound can also be utilized in the treatment of bacterial 
contaminations caused by rejection or epidemic nosocomial 
infections, piodermic infections and skin ulcers. NTZ is ef-
fective against a significative number of microorganisms, 
including Staphylococcus aureus and Escherichia coli, but 
however does not possess significative activity against 
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Pseudomonas aeruginosa, Proteus mirabilis and Serratia 
marcescens [2]. Considering the cutaneous route of admini-
stration and the release of active substances on the epider-
mis, in many cases, there is an interest to maximize the resi-
dence time of the compound on the skin, minimizing its 
transdermal absorption. Among the structures used for the 
controlled release of drugs, one may find liposomes, mi-
croparticles (microcapsules and microspheres) and nanopar-
ticles (nanospheres and nanocapsules) [3, 4]. Microencapsu-
lation is a process by which solids, liquids and even gases 
may be captured within microscopic particles through the 
formation of a thin layer around the substance. The capsules 
formed may release the content in a controlled fashion and 
under specific conditions. In the pharmaceutical industry, the 
microencapsulation technology has been applied for masking 
odors or flavors, conversion of liquids into solids, protection 
against atmospheric (abiotic) agents (humidity, light, heat 
and/or oxidation), reduction or elimination of gastric irrita-
tion or secondary effects caused by certain drugs, reduction 
of volatility, administration of incompatible drugs, im-
provement of the flow characteristics of powders, facilitation 
of the handling of toxic substances, aid in the dispersion of 
water-insoluble substances in aqueous media, among other 
functions [5, 6]. There is a wide variety of methods for pre-
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paring polymeric microspheres and microcapsules, which 
allows the incorporation of water soluble or fat soluble 
drugs. The selection of these techniques is dependent on the 
application to be given to the microcapsule, on the size de-
sired, on the release mechanism and the physicochemical 
properties of both the active material and the encapsulating 
agent. Adding to this, for choosing the most appropriate 
method one should also consider the simplicity, reproducibil-
ity and feasibility of scaling [4, 5]. The main techniques used 
for the placement of active ingredients include mechanical, 
physical and chemical methods. Additionally, various poly-
mers can also be used in the production of microparticles and 
their choice depends on the application requirements [7]. In 
the method involving physicochemical extrusion/solidification, 
the core material in liquid form, molten or in solution, is 
forced through an orifice (a thin tube or syringe) to form 
microdroplets whose size will be dependent on the diameter 
of the orifice and the exit speed of the material. The solidifi-
cation of the coating material can occur by evaporation of 
the solvent, diffusion of the solvent or by chemical reaction. 
The extrusion method with ionotropic crosslinking is widely 
used in the encapsulation of drugs, being based on the reac-
tion between divalent cations and some polymers with for-
mation of interchain junctions (crosslinked) to obtain hydro-
gels [7, 8]. As encapsulating agents there is a wide range of 
choices of raw materials. Among them, one can mention 
alginates, which are polysaccharides derived from alginic 
acid, which in turn is obtained mainly from seaweed of the 
species Laminaria. This biopolymer belongs to the class of 
binary copolymers, containing β(1->4) bonds of D-
manuronic (M) acid and α -L-guluronic (G) acid, with wide 
variation in composition and sequential structure. Alginates 
possess unique colloidal properties such as natural compres-
sion, stabilization, suspension, film-forming, emulsion and 
gel formation. Alginates also have a unique feature, which is 
its willingness to react with polyvalent cations, especially 
calcium ions, thus resulting in stronger gels or insoluble 
polymers [9, 10]. The major goal of the research effort enter-
tained herein was to prepare and characterize calcium algi-
nate microparticles encapsulating NTZ, with concomitant 
use in the preparation of pharmaceutical formulations in the 
form of gels for topical applications. 
2. MATERIAL AND METHODS 
2.1. Reagents 
 All reagents utilized in this research work were of phar-
maceutical purity or PA grade, and were used without further 
purification. The water used was purified in a Milli-Q Elga 
Purelab system (Molsheim, France) to a final conductivity of 
ca. 18.2 MΩ•cm-1. Sodium alginate (low viscosity) 90.8%-
106.0% dry weight (w/w), lot 1000896, and sodium alginate 
(high viscosity) 90.8%-106.0% dry weight (w/w), lot 0805920, 
were purchased from Vetec Química fina Ltda (Rio de Ja-
neiro, Brazil); Anhydrous calcium chloride (powder, PA, lot 
07060931) was purchased from CAQ - Casa da Química 
(Diadema, São Paulo, Brazil); Nitrofurazone (C.A.S. 59-87-0, 
molecular formula C6 H6N4O4) 97.3% pure (dry weight basis, 
w/w), of chineese origin, was a kind gift by Henrifarma Pro-
dutos Químicos e Farmacêuticos Ltda (São Paulo, Brazil). 
Polyethyleneglycol 300 (lot 110217C914C2) was purchased 
from Labsynter - Produtos para Laboratório Ltda (Diadema, 
São Paulo, Brazil). BHI nutritive broth (Brain Heart Infu-
sion) was purchased from Fluka (St. Louis MO, U.S.A.). 
Mannitol Salt Agar was purchased from Prodimol Biotec-
nologia/SA (São Paulo SP, Brazil). 
2.2. Biological Material 
 The microbial strains used were a kind gift from the Mi-
crobiology Laboratory of UBM (University Centre of Barra 
Mansa/RJ, Brazil), consisting in a strain of Escherichia coli 
(ATCC 25922, beta-lactamase negative), a strain of Pseudo-
monas aeruginosa (ATCC 27853), and a strain of Staphylo-
coccus aureus (ATCC 250923, susceptible to oxacillin and 
penicillin). 
2.3.Experimental procedures 
2.3.1. Preparation of Microparticles Containing Encapsu-
lated NTZ 
 Microparticles containing encapsulated NTZ were pre-
pared by extrusion/solidification, via ionotropic gelification 
of sodium alginate in a three-step sequential procedure. The 
final formulation can be found in Table 1. In step I, (prepa-
ration of the nitrofurazone and sodium alginate solution), one 
has determined initially the best proportion between low- 
and high-viscosities sodium alginate. For this, the percent 
relationships 40:60, 50:50 and 60:40 of low-viscosity and 
high-viscosity sodium alginates, respectively, were tested. 
Nitrofurazone and sodium alginate were weighed separately, 
and 95 mL of ultrapure water were heated up to 60°C. The 
heated ultrapure water was then added slowly to the sodium 
alginate until its full dissolution, under magnetic stirring 
during ca. 10 min, using a magnetic stirring device from 
Fisaton (model 752 A, São Paulo, Brazil). Following forma-
tion of an homogeneous alginate gel, powder nitrofurazone 
was then added under manual stirring during ca. 2 min. In 
step II (extrusion), the homogeneous dispersion produced in 
step I was allowed to stand at rest during ca. 30 min until 
attaining room temperature (25°C), after which it was trans-
ferred into the reservoir of a compressed-air painting gun 
from Mac Loren (model P-100, Garça, Brazil). The sodium 
alginate-NTZ dispersion, under pressure, was then sprayed 
over a calcium chloride solution (1.5%, w/w) at room tem-
perature (25°C), thus producing calcium alginate microparti-
cles that remained scattered within the calcium chloride solu-
tion. Following their production, the microparticles were 
filtered and placed into another calcium chloride (2%, w/w) 
solution for an extra 30 min. In step III (drying), the mi-
croparticles produced were filtered in a sieve from Ber Tel 
(mesh of 180 mm, Caieiras, Brazil), and were allowed to dry 
at room temperature (25°C) during 24 h in the absence of 
light. 
2.3.2. Physico-chemical Characterization of the Micropar-
ticles Containing Encapsulated Nitrofurazone 
 The microparticles containing encapsulated nitrofurazone 
were characterized, physico-chemically, via (i) evaluation of 
their microstructural morphology using scanning electron 
microscopy, (ii) determination of the amoung of drug associ-
ated to the microparticles by UV-Vis spectrophotometry, (iii) 
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study of the NTZ association pattern to the reactants utilized 
to produce the microparticles, via both thermal analyses 
(TGA and DSC) and infrared spectrophotometry with Fou-
rier transform (FTIR), and (iv) rheology studies. 
 
Table 1. Composition of the calcium alginate microparticles 
with encapsulated nitrofurazone, produced via the 
extrusion/solidification technique. 
Component 	  
Concentration 
(%, w/w) 
60:40 (%, w/w) of high viscosity sodium alginate 
and low viscosity sodium alginate  
2.0 
Nitrofurazone  0.2 
Calcium chloride  2.0 
Ultrapure water  Sat 100% 
Notes: Sat – Sufficient amount to. 
 
2.3.2.1. Structural Microanalysis of the Microparticles 
Containg Encapsulated Nitrofurazone via SEM 
 The surface of the microparticles containing encapsulated 
nitrofurazone was duly observed in a scanning electron mi-
croscope (from JEOL, model JSM-63660 CV, Tokyo, Ja-
pan). Microparticle samples were sputter coated with colloi-
dal gold under vacuum, and placed in the microscope cham-
ber. Microphotographs were gathered using electron beams 
with acceleration speeds of 10-20 keV. The samples were 
randomly scanned and photomicrographed at magnifications 
of x200 up to x300. 
2.3.2.2. Thermal Analyses (TGA and DSC) 
 The thermogravimetric characterization of the micropar-
ticles was accomplished via thermogravimetric analysis 
(TGA) whereas the thermal analyses was pursued by differ-
ential scanning calorimetry (DSC). The TGA analyses were 
carried out using a thermogravimeter from TA Instruments 
(model 2050, New Castle, U.S.A.). For the DSC analyses 
one has used a differential scanning microcalorimeter from 
TA Instruments (model MDSC 2910, New Castle, U.S.A.), 
with the microparticle samples being subjected to a linear 
temperature increase from ca. 20°C up to 300°C, at a con-
stant heating rate of 10°C min-1. 
2.3.2.3. Analyses via Infrared Spectrophotometry with Fou-
rier Transform 
 The infrared spectra of both pure nitrofurazone and sam-
ples of microparticles containing encapsulated nitrofurazone 
were gathered in the range of wave number from 4000 to 100 
cm-1 during 64 scans, with a resolution of 4 cm-1, using an 
infrared spectrophotometer (Illuminat IR II from Smiths, 
Watfords, England) with Fourier transform. FT-IR spectra 
were obtained using an infrared microprobe (Illuminat IR, 
model II, from Smiths, Watfords, England), coupled with an 
optical microscope (from Olympus, model BX51, Tokyo, 
Japan). 
2.3.2.4. Determination of the Nitrofurazone Content of the 
Microparticles and of the Encapsulation Efficiency 
 The amount of nitrofurazone incorporated within the mi-
croparticles was calculated by the difference between the 
total concentration of NTZ offered to produce the dispersion 
of NTZ-sodium alginate and the concentration of free NTZ 
in the supernatant (calcium chloride solution) after the en-
capsulation process. The amounts of NTZ were determined 
spectrophotometrically in the UV-Vis at a wavelength of 375 
nm [11] using a Multispec spectrophotometer from Shima-
dzu (model 1501, Kyoto, Japan). 
2.3.3. Preparation of the Pharmaceutical Formulation in 
the Form of a Gel for Topical Application 
 For the preparation of the pharmaceutical formulation in 
the form of a gel, all components were weighed separately. 
90 mL of ultrapure water were heated up to ca. 60°C, in a 
250 mL beaker, and Aristoflex® was slowly added under 
manual stirring until obtention of a translucent and viscous 
gel. Slowly and with constant manual stirring, the remaining 
components were also added (propyleneglycol, polyethyle-
neglycol), as well as the preservative mixture (phenoxyetha-
nol, methylparaben, propylparaben). After the gel prepara-
tion was complete, it was left standing for ca. 30 min until 
attaining room temperature (25°C). Next, the microparticles 
containing encapsulated nitrofurazone were duly added to 
the gel and the resulting preparation was thoroughly and 
carefully homogeneized so as to fully disperse the micropar-
ticles in the gel. To evaluate the physico-chemical 
characteristics of the gel containing microparticles with 
encapsulated nitrofurazone, two gels were prepared, one 
without microparticles and another with free nitrofurazone, 
according to the same aforementioned procedure. The 
formulations produced are detailed in Table 2. 
2.3.4. Characterization of the Gel Integrating Microparti-
cles with Encapsulated Nitrofurazone 
 The gel integrating microparticles with encapsulated ni-
trofurazone was characterized from the point of view of its 
viscosity, content of active principle, photostability and an-
timicrobial activity, according to the procedures described 
next. 
2.3.4.1. Photostability Assays 
 The gel photostability assays were performed according 
to the procedures described by Melo et al. [12]. As light 
source, a UV lamp was used, placed inside a chamber with 
dimensions 20cm x 27cm x 23cm, with the gel sample being 
irradiated at a distance of 18 cm from the lamp. The photo-
stability assays were carried out by exposing ca. 10 g of the 
gels in Petri dishes isolated with polyethylene film (to avoid 
water evaporation and concomitant mass losses). The photo-
stability assays were performed in samples of Aristoflex® 
AVC (control sample), Aristoflex® AVC gel integrating free 
nitrofurazone, and Aristoflex® AVC gel integrating mi-
croparticles with encapsulated nitrofurazone. To determine 
the content in nitrofurazone and its relationship with photo-
stability, samples were withdrawn at time intervals of 60 min 
during a total timeframe of 3 h of UV exposure. After this 
time period, all samples were maintained under UV light for 
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24 h. The amount of nitrofurazone in the samples was deter-
mined by UV-Vis spectrophotometry at a wavelength of  
375 nm [11]. 
2.3.4.2. Rheological Characterization of the Gels Produced 
 The viscosity of the several gels produced was deter-
mined using a rheometer from Brookfield (model Dv I 
Prime, U.S.A.). For the gel samples containing microparti-
cles with encapsulated nitrofurazone, Brookfield spindles 
with references S-05, S-06 and S-07 were used, at a rotation 
speed of 10 rpm and at room temperature (25°C). All analy-
ses were performed in triplicate. Besides viscosity values, 
the rheometer software also provided shear stress data as a 
function of shear rate, and therefore this information was 
also used for the rheological characterization of the samples 
of the various gels produced. 
2.3.4.3. Determination of Nitrofurazone Content by UV-Vis 
Spectrophotometry 
 The methodology utilized for determination of the nitro-
furazone content was the one developed by [11] involving 
UV-Vis spectrophotometry, using polyethyleneglycol to dis-
solve nitrofurazone, with absorbance readings at a wave-
length of 375 nm. 
2.3.4.4. Microbiological Assays via the Agar Diffusion 
Method 
 The antimicrobial efficacy of the gel integrating mi-
croparticles with encapsulated nitrofurazone was determined 
by applying the agar diffusion technique described by Bauer 
et al. [13] and Jorgensen et al. [14], as well as according to 
the standards of the Clinical and Laboratory Standards Insti-
tute [15]. The assays were carried out using a strain of 
Staphylococcus aureus (CCCD S007 - Cefar Diagnóstico 
Ltda, São Paulo, Brazil). The Staphylococcus aureus strain 
was, initially, inoculated in BHI nutritive broth (Brain Heart 
Infusion) and maintained at 37°C ± 0.5°C during 24 h, to 
allow growth of the bacteria. Following this time period, the 
bacterial culture was inoculated into grooves on two Petri 
dishes containing Mannitol Salt Agar as culture medium. 
The samples to be tested were then applied on the inoculated 
medium, in duplicate: quadrant 1 - gel optimized with 4% 
(w/w) ARISTOFLEX®, without microparticles with encap-
sulated nitrofurazone (negative inhibition standard); quad-
rant 2 - optimized gel with 4% (w/w) ARISTOFLEX® inte-
grating microparticles with encapsulated nitrofurazone; 
quadrant 3 - sterile filter paper disc, impregnated with a 
0.2% (w/v) solution of nitrofurazone in propyleneglycol 
(positive inhibition standard); and quadrant 4 - sterile filter 
paper disc, impregnated with propyleneglycol (negative in-
hibition standard). Propyleneglycol and the solution of nitro-
furazone in propyleneglycol were impregnated in sterile fil-
ter paper discs 7.0 mm in diameter, and inoculated in the 
Petri dishes with the aid of sterile tweezers near a Bunsen 
burner flame. The gel samples were inoculated in the Petri 
dishes with the aid of a sterile loop. The Petri dishes were 
then inverted and incubated under aerobic conditions at 37°C 
± 0.5°C during 48 h. After this time period, the plates were 
visually inspected for observation (or not) of any growth 
inhibition halos. 
3. RESULTS AND DISCUSSION 
3.1. Production of Calcium Alginate Microparticles with 
Encapsulated Nitrofurazone 
 For the production of calcium alginate microparticles, the 
extrusion/solidification technique was applied. Sodium algi-
nate is extensively used as encapsulating material, since it is 
a natural polymer of relatively low cost and easily obtain-
able, biocompatible, non-toxic and biodegradable. Having 
these features in mind, sodium alginate has been used to pre-
pare microparticles containing different active principles and 
in different processes [10, 16,]. The extrusion/solidification 
Table 2. Formulations developed to produce the gels with calcium alginate microparticles with encapsulated nitrofurazone, plain 
gels without any microparticles, and gels with added free (pure) nitrofurazone. 
Concentration (%, w/w)	  
Formulation component	   Gel with embedded calcium 
alginate microparticles with 
encapsulated nitrofurazone 
Gel with added free  
nitrofurazone 
Gel without calcium alginate 
microparticles with  
encapsulated nitrofurazone 
Aristoflex® AVC 	   4.0%	   4.0%	   4.0%	  
Calcium alginate microparticles with encapsula-
ted nitrofurazone 	  
0.2%	   -----	   -----	  
Propyleneglycol 	   5.0%	   5.0%	   5.0%	  
(free) Nitrofurazone 	   -----	   0.2%	   -----	  
Phenoxyethanol 	   0.4%	   0.4%	   0.4%	  
Methylparaben 	   0.15%	   0.15%	   0.15%	  Preservative solution	  
Propylparaben 	   0.02%	   0.02%	   0.02%	  
Ultrapure water *Sat 100% *Sat 100% *Sat 100% 
Notes: Sat – quantidade suficiente para. 
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technique requires that the drug is added to a dispersion of 
sodium alginate and then this dispersion is extruded, with the 
particles being collected in a calcium chloride solution. The 
extrusion/solidification process using alginate occurs via 
ionotropic gelation of sodium alginate. The ionotropic gela-
tion of sodium alginate occurs upon binding of divalent cal-
cium ions to blocks of guluronic acid from the alginate 
chains, constituting the so-called "egg-box" model [17]. To 
obtain particles with uniform size, with maintenance of their 
shape after drying, the tests were focused in the definition of 
the most appropriate sodium alginate, by using low- and 
high-viscosity sodium alginate in different mass proportions. 
The best mass proportion found was 60:40 of high-viscosity 
sodium alginate and low-viscosity sodium alginate, respec-
tively. The microparticles produced with this proportion of 
high- and low-viscosity sodium alginates were homogeneous 
in size and presented an adequate resistance. Regarding the 
extrusion process, a positive-pressure painting gun was 
found to be the most adequate method, producing micropar-
ticles with uniform conformations and reduced size. 
3.2. Physico-chemical Characterization of the Particles 
Produced 
3.2.1. SEM Analyses 
 The particles produced were fully characterized with re-
spect to their morphology via scanning electron microscopy 
(SEM), nitrofurazone encapsulation efficiency, infrared 
spectrophotometry with Fourier transform, and thermal 
analyses via both TGA and DSC. The SEM analyses re-
vealed particles with sizes between 500 and 800 µm and with 
a slightly oval shape (Fig. 1). The particles produced can, 
therefore, be characterized as microparticles, since the spec-
trum of sizes for microparticles varies between 1 and 1000 
µm [18, 19]. According to Wang et al. [20], the concentra-
tion of sodium alginate may influence the particle shape and, 
usually, a mass concentration of sodium alginate between 0.8 
and 1.5% is used to produce microparticles. These authors 
also consider that, when the percentage of sodium alginate is 
higher than the values cited the particles may present an oval 
shape. This was in fact observed in the present research ef-
fort, since the formulation optimized integrated 2.0 % (w/w) 
of sodium alginate. Naturally, beyond polymer concentra-
tion, the shape of the particles can also be strongly influ-
enced by the extrusion process employed, temperature and 
feeding rate to the extruder device, amongst other factors. 
3.2.2. FTIR Analyses 
 In (Fig. 2), one can see the infrared spectra of the calcium 
alginate microparticles with encapsulated nitrofurazone (Fig. 
2a), of the calcium alginate microparticles without nitrofura-
zone (see Fig. 2b), and of pure nitrofurazone (Fig. 2c). In the 
infrared spectra of the calcium alginate microparticles, with 
and without encapsulated nitrofurazone, one can observe a 
peak in the wave number close to the region of 1590 cm-1, 
probably indicating the presence of calcium ions [21]. The 
peak in the wavelength region of 3500 cm-1, characteristic of 
the stretching of the OH and bond with water [22], is ob-
served in all spectra. By comparing the infrared spectra of 
the calcium alginate microparticles with and without encap-
sulated nitrofurazone, one can see that there is no displace-
ment of the main peaks, only a change in intensity. This may 
indicate that nitrofurazone has not established a strong con-
nection with the polymer. 
 
  
Fig. (1). Scanning electron microphotograph of a calcium alginate 
microparticle with encapsulated nitrofurazone, at different magnifi-
cations: (a) x200; (b) x300. 
 
3.2.3. Encapsulation Efficiency 
 The efficacy of encapsulation is the ratio between the 
amount of encapsulated substance in the microparticles and 
the (total) amount of theoretical active employed. The encap-
sulation efficiency of active principles encountered in the 
specialty literature varies widely. Soni et al. [23] point, gen-
erally, to an encapsulation efficiency in the magnitude of 70-
93%. However, according to Schaffazick et al. [24], this 
range of encapsulation efficiencies can vary even more, indi-
cating association rates of some drugs from 39% to 100%. 
The encapsulation efficiency produced in the present re-
search effort was of 97.8% ± 1.1%, a value which is in good 
agreement with those reported by Honary et al. [25] for the 
encapsulation efficiency of prednisone in microparticles of 
alginate and chitosan, viz. from 98.97% ± 0.97% to 96.68% 
± 0.40%. The rate of encapsulation varies as a function of 
several parameters, viz. the process utilized to produce the 
nano/microparticles, the type of drug selected, type and con-
centration of the polymer employed, rate of solvent elimina-
tion, solubility of the polymer in the solvent, amongst other 
factors [24]. Hence, the values for the encapsulation effi-
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ciency produced in the research effort entertained herein can 
be considered as very good. 
 
 
Fig. (2). Infrared spectra of (a) calcium alginate microparticles with 
encapsulated nitrofurazone, of (b) plain calcium alginate micropar-
ticles without nitrofurazone, and of (c) pure nitrofurazone. [Proc-
essing parameters: Image (magnification, x36.0; width, 252.1 µm; 
height, 189.0 µm); experimental (analysis scans, 64; background 
scans, 64; resolution of 4 cm-1; spectral range, 4000.0-100.0 cm-1; 
detector type, MCT; objective, 36X-ATR)]. 
3.2.4. Thermal Analyses 
 The DSC analyses of calcium alginate microparticles 
without encapsulated nitrofurazone (see Fig. 3b) allows  
observation of a major endothermal event (melting) at 
212.62ºC. Regarding the calcium alginate microparticles 
with encapsulated nitrofurazone (Fig. 3a), the DSC analyses 
produced a melting temperature of 213.40ºC. When compar-
ing these temperatures a slight shift can be observed, which 
may potentially indicate that nitrofurazone was not strongly 
bound to the polymer. 
 The TGA curve of the microparticles with encapsulated 
nitrofurazone (Fig. 4a) showed three significant thermal 
events, with the first thermal event with loss of water occur-
ring from 58.40°C to 89.00°C (78.31% mass loss). The sec-
ond thermal event occurred at 192.46°C, and may probably 
indicate the formation of calcium carbonate (1.69% mass 
loss), whereas the third thermal event which may have ac-
counted for the carbonization of the polymer chains occurred 
in the range of 286.87°C to 640.80°C (1.045% plus 1.050% 
mass losses). The analysis of the TGA curve of the calcium 
alginate microparticles without encapsulated nitrofurazone 
(Fig. 4b) indicated a significant mass loss (42.12%) starting 
at 55.94°C, probably due to the elimination of water. At 
291.16°C, a 16.58% mass loss occured, probably due to car-
bonization of the polymer chains. Hence, one can infer that 
when compared to the plain calcium alginate microparticles, 
the calcium alginate microparticles with encapsulated nitro-
furazone are more prone to decomposition. 
3.3. Physico-chemical Characterization of the Gel Pro-
duced 
 Generally, the substances responsible for the formation 
of gels are polymers that, when dispersed in an aqueous me-
dium, assume a conformation that confers increased viscos-
ity to the formulation. The type and percentage of polymer 
used in the formulation can affect the rheological behavior of 
the pharmaceutical formulation and hence influence the 
physical stability of the product [26]. Therefore, for the qual-
ity control of the product developed one performed several 
assays to verify the stability of the product’s viscosity upon 
storage, determined the drug content, and assessed the pho-
tostability and antimicrobial efficacy. 
3.3.1. Rheological Analyses 
 In semi-solid dosage forms, the determination of 
rheological characteristics is fundamental in assessing the 
quality of the product and its consequent acceptance by the 
consumer. The rheological characteristics are important 
properties to be considered in the manufacture, storage and 
application of topical products, and can influence parameters 
such as the physical stability of the system, spreadability and 
sensory characteristics, as well as the purposes of use [26]. 
In the research effort entertained herein, gels produced at 
concentrations ranging from 2.5% (w/w) to 5.0% (w/w) of 
ARISTOFLEX® AVC were evaluated for viscosity, to define 
the best percentage of gelling agent. These analyses proved 
necessary because the incorporation of calcium alginate mi-
croparticles with encapsulated nitrofurazone caused a reduc-
tion in viscosity in the original formulation. The rheological 
behavior of semi-solid pharmaceutical forms can be evalu-
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ated via measurements of viscosity, using a viscosimeter. All 
analyses were performed in triplicate at 0, 30, 45, 60, 75 and 
90 days of storage. From the results obtained (Fig. 5) it can 
be seen that the percentage of gellifying agent which resulted 
in the better outcome in relation to the formulation’s viscos-
ity was 4% (w/w) of ARISTOFLEX® AVC. During the 90 
days of storage, the gel produced with 4% (w/w) ARISTO-
FLEX® AVC maintained a proper viscosity, thus maintain-
ing the expected characteristics of a formulation for topical 
use. Hence, the gel produced with 4% (w/w) ARISTO-
FLEX ® AVC was the formulation of choice for carrying the 
calcium alginate microparticles with encapsulated nitrofura-
zone. 
 The rheological behavior of the gel was also evaluated, 
being considered shear thinning since the apparent viscosity 
gradually decreases with increasing shear stress. The results 
obtained (Fig. 6) were characteristic of pseudoplastic fluid. 
The shear thinning behavior is more common among non-
Newtonian fluid, also called shear-thinning and reflects a 
temporary change in the structure of molecules during shear. 
  
Fig. (3). Differential scanning calorimetry (DSC) analyses of (a) calcium alginate microparticles with encapsulated nitrofurazone and of (b) 
plain calcium alginate microparticles (without nitrofurazone). 
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Fig. (4). Thermogravimetric curves (TGA) of (a) calcium alginate microparticles with encapsulated nitrofurazone and of (b) plain calcium 
alginate microparticles (without nitrofurazone). 
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Fig. (5). Viscosity of the gel as a function of gellifying agent concentration (Aristoflex® AVC) (2.5; 3.0; 3.5; 4.0 and 5.0%, w/w), after a stor-
age timeframe of 90 d. 
 
  
Fig. (6). Rheogram (shear stress as a function of shear rate) of the final gel formulation with 4% (w/w) Aristoflex® AVC, with embedded 
calcium alginate microparticles with encapsulated nitrofurazone. 
 
3.3.2. Determination of NTZ Concentration via UV-Vis 
Spectrophotometry 
 For the determination of nitrofurazone concentration in 
the final gel formulation integrating calcium alginate mi-
croparticles with encapsulated nitrofurazone, the spectropho-
tometric methodology described by Tubino et al. [11] was 
utilized, with absorbance readings at 375 nm. Initially, one 
has verified the linearity of the spectrophotometric method, 
by using nitrofurazone solutions with concentrations ranging 
from 2.0 mg L-1 to 20.0 mg L-1, which produced the linear 
relationship Abs@375nm = 0.089 x [NTZ, mg L-1] - 0.007, 
with a correlation coefficient (R2) equal to 0.999. The preci-
sion of the NTZ concentrations analyzed (2.5, 10, 12.5, 20 
mg L-1) exhibited a coefficient of variation between 0.27 and 
0.47%, an accuracy between 99.87% and 109.36%. The 
quantification and detection limits were of 0.04 mg L-1 and 
0.01 mg L-1, respectively, meaning that all parameters con-
sidered were adequate for the analysis proposed. Through the 
data gathered in the determination of nitrofurazone concen-
tration in samples of gels containing calcium alginate mi-
croparticles with encapsulated nitrofurazone, one obtained a 
content in active drug of ca. 0.18% ± 0.05%, meaning that 
the final gel formulation contained 90% of the drug content 
offered to produce the formulation. The technique employed 
to prepare the gel formulation consisted in adding the mi-
croparticles to the gel. Perhaps, by using the suspension of 
microparticles itself as the aqueous phase in the preparation 
of the gel, one could maintain the nitrofurazone concentra-
tion of 0.2% (w/w), considered as appropriate for the active 
drug used. 
3.3.3. Photostability Assays 
 Nitrofurazone is a drug that, when exposed to sun light, 
undergoes isomerization with formation of red-yellowish 
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compounds. The photodegradation process of nitrofurazone 
may be explained by a kinetic model involving three first-
order reactions [27]. To ensure a constant effectiveness for 
the developed formulations, the gels were subjected to UV 
light irradiation in a UV light chamber, according to the pro-
cedure described by Melo et al. [12], and the levels of active 
drug were assessed via spectrophotometry. For this purpose, 
analyzes were performed on the gels produced with 
ARISTOFLEX® AVC at the concentrations of 2.5%, 3.0%, 
3.5%, 4.0%, and 5.0% (w/w) and integrating microparticles 
with encapsulated nitrofurazone. For the purpose of com-
parison of the results, one subjected to the same conditions a 
gel of ARISTOFLEX® AVC added with free nitrofurazone 
and a gel of ARISTOFLEX® AVC without addition of either 
microparticles containing encapsulated nitrofurazone or free 
nitrofurazone. Table 3 presents the results encountered for 
the concentration of nitrofurazone following exposure of the 
gel samples to UV light radiation after 1 h, 2 h, 3 h and 24 h 
of exposure. After 3 h of exposure to UV radiation, there was 
no significative variation in the produced contents of nitro-
furazone, and thus one opted to determine the nitrofurazone 
content after 24 h of exposure to UV radiation. It can be seen 
that, after 24 h of exposure, the amount of nitrofurazone ex-
hibited higher values in all formulations. This is an indica-
tion that there was nitrofurazone degradation in all formula-
tions, since the spectrophotometric method employed does 
not allow differentiation between the active drug and its deg-
radation products. It can be concluded, therefore, that the 
topical product developed requires protection from light so 
as to maintain its integrity. 
3.3.4. Anti-microbial Assays 
 Staphylococcus aureus was the pathogenic microorgan-
ism chosen to test the antimicrobial activity of optimized gel 
incorporating calcium alginate microparticles containing 
encapsulated nitrofurazone. Since this is an opportunistic 
pathogen, S. aureus is one of the main responsibles for infec-
tions in burn and surgical wounds [28]. Additionally, S. 
aureus is susceptible to the antimicrobial action of nitrofura-
zone when in doses greater than or equal to 4 µg mL-1, ac-
cording to Yilmaz et al. [29]. From a close inspection of 
(Fig. 7), one can notice that microparticles are capable of 
releasing the encapsulated nitrofurazone, which may allow 
the use of calcium alginate microparticles containing encap-
sulated nitrofurazone in pharmaceutical formulations for 
topical use. In fact, a careful inspection of (Fig. 7) (quadrant 
2) reveals that application of the gel containing the micropar-
ticles with encapsulated nitrofurazone inhibits microbial 
growth (unlike the gel without incorporated microparticles, 
see quadrant 1 in Fig. 7), while the disk impregnated with 
0.2% (w/v) nitrofurazone in propylene glycol produced a 
clear halo of inhibition of bacterial growth. 
 To eliminate any possibility of antimicrobial action of the 
solvent used for nitrofurazone, a sterile disk was impreg-
nated with propylene glycol and also applied on the inocu-
lated culture, and the result was clearly negative in terms of 
inhibition of bacterial growth (quadrant 4 in Fig. 7). Hence, 
the results clearly demonstrate the antimicrobial activity of 
the gel produced in this research effort, which integrated 
calcium alginate microparticles containing encapsulated ni-
trofurazone. 
CONCLUSIONS 
 The system used to obtain calcium alginate microparti-
cles at the lab scale proved to be effective, producing a high 
encapsulation efficiency of the drug. The physico-chemical 
analyses performed indicated microparticles with uniform 
size and with little interaction with the polymer employed in 
the process. These characteristics are appropriate to ensure 
the functionality of this type of drug release system. Incorpo-
ration of the calcium alginate microparticles into the initial 
gel formulation caused its destabilization, and thus a reset-
ting of the content of gelling agent was required. After modi-
fication of the initial formulation, the gel presented stable 
viscosity and a good appearance. The gel embedded with 
calcium alginate microparticles containing encapsulated ni-
trofurazone also exhibited an appropriate antimicrobial activ-
ity for a product for topical use and drug content within ac-
Table 3. Nitrofurazone concentration in the gels after exposure to UV radiation, produced by a UV Mineralight Lamp - UVGL-58 
(254nm). 
Nitrofurazone concentration (%, w/w) as a function of exposure time to UV radiation Gels produced with different concentrations 
(w/w) of Aristoflex®AVC	   1 h	   2 h	   3 h	   24 h	  
2.5 % *	   0.151	   0.151	   0.156	   0.172	  
3.0 %*	   0.203	   0.203	   0.196	   0.228	  
3.5 %*	   0.223	   0.220	   0.190	   0.273	  
4.0 %*	   0.129	   0.150	   0.132	   0.191	  
4.5 %*	   0.262	   0.271	   0.285	   0.359	  
5.0 %*	   0.202	   0.208	   0.174	   0.193	  
2.0% with nitrofurazone**	   0.1278	   0.1309	   0.1439	   0.1711	  
2.0% without nitrofurazone***	   0.0093	   0.0093	   0.0091	   0.0097	  
Notes: *Gel with 0.2% (w/w) embedded calcium alginate microparticles with encapsulated nitrofurazone; **Gel produced with 2.0% (w/w) Aristoflex® AVC and 0.2% (w/w) free 
nitrofurazone; ***Gel produced with 2.0% (w/w) Aristoflex® AVC without nitrofurazone. 
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ceptable parameters. From the results obtained in the re-
search effort entertained herein, the pharmaceutical dosage 
form proposed exhibited promising qualities for use as a 
topical antimicrobial gel. 
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